混合纳米粒子-水凝系统用于药物输送仓库和其他生物医学应用
Wonmin Choi1, Daniel S Kohane1
1Laboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
ACS nano
|August 14, 2024
概括
混合纳米粒子-凝系统将局部的凝输送与纳米粒子 (NP) 的受控释放相结合. 这种方法克服了改善药物输送应用程序的个体物质限制.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 水凝储存提供了出色的生物相容性和保留位置,但药物释放控制不佳.
- 纳米粒子 (NP) 提供可调节的药物释放,但可以具有可变的生物相容性,易于迁移.
- 在注射系统中实现局部传递和受控释放存在重大差距.
研究的目的:
- 审查开发混合纳米粒子-水凝系统背后的逻辑.
- 概述生产这些复合药物输送车辆的基本方法.
- 介绍一些NP-水凝系统的例子,以解决特定的药物输送挑战.
主要方法:
- 对NP-水凝复合材料现有研究的文献综述.
- 对混合系统的材料性能和制造技术的分析.
- 在药物输送中成功使用NP-水凝的案例研究.
主要成果:
- 混合系统协同结合了水凝的局部化和NP的受控释放.
- 制造方法允许量身定制的NP封装和水凝矩阵形成.
- 具体的例子表明,治疗效率提高,副作用减少.
结论:
- 混合NP-水凝系统是克服独立水凝和NP的局限性的有希望的策略.
- 这些复合材料为先进的药物输送提供了多功能平台.
- 对NP-水凝系统的进一步研究对于各种治疗应用是有必要的.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
211
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
211


